PALM BEACH GARDENS, Fla. & NEEDHAM, Mass.--(BUSINESS WIRE)--Xcovery, a developer of targeted therapeutics for cancer, today announced that data on the plasma genotyping of patients enrolled in its expansion Phase I/II trial of ensartinib (X-396), the Company’s lead ALK inhibitor drug candidate, in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, which is being held from June 3 - 7, 2016 in Chicago, Illinois. The presentation details are as follows:
